1887

n African Journal of Psychiatry - SGAs and the metabolic syndrome : product news

USD

 

Abstract

Second-generation antipsychotics (SGAs) are an effective treatment for patients with schizophrenia but there is substantial evidence that certain of these agents are associated with clinically significant weight gain, increased risk for insulin resistance, hyperglycemia and dyslipidemia compared with first-generation antipsychotics.

Loading

Article metrics loading...

/content/medjda2/12/4/EJC72754
2009-11-01
2016-12-08
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error